Skip to main content
Top
Published in: EJNMMI Research 1/2015

Open Access 01-12-2015 | Original research

Absorption, distribution and excretion of intravenously injected 68Ge/68Ga generator eluate in healthy rats, and estimation of human radiation dosimetry

Authors: Anu Autio, Helena Virtanen, Tuula Tolvanen, Heidi Liljenbäck, Vesa Oikonen, Tiina Saanijoki, Riikka Siitonen, Meeri Käkelä, Andrea Schüssele, Mika Teräs, Anne Roivainen

Published in: EJNMMI Research | Issue 1/2015

Login to get access

Abstract

Background

This study evaluated the absorption, distribution, and excretion of Gallium-68 (68Ga) radionuclide after a single intravenous (i.v.) injection of 68Ge/68Ga generator eluate in healthy rats. Additionally, human radiation doses were estimated from the rat data.

Methods

Twenty-one female and 21 male Sprague-Dawley rats were i.v. injected with 47 ± 4 MBq of 68Ge/68Ga generator eluate, and the radioactivity of excised organs was measured using a gamma counter at 5, 30, 60, 120, or 180 min afterwards (n = 3–7 for each time point). The radioactivity concentration and plasma pharmacokinetic parameters were calculated. Subsequently, the estimates for human radiation dosimetry were determined. Additionally, 4 female and 5 male rats were positron emission tomography (PET) imaged for in vivo visualization of biodistribution.

Results

68Ga radioactivity was cleared relatively slowly from blood circulation and excreted into the urine, with some retention in the liver and spleen. Notably, the 68Ga radioactivity in female genital organs, i.e., the uterus and ovaries, was considerable higher compared with male genitals. Extrapolating from the female and male rat 68Ga data, the estimated effective dose was 0.0308 mSv/MBq for a 57-kg woman and 0.0191 mSv/MBq for a 70-kg man.

Conclusions

The estimated human radiation burden of the 68Ge/68Ga generator eluate was slightly higher for females and similar for males as compared with somatostatin receptor ligands 68Ga-DOTANOC, 68Ga-DOTATOC, and 68Ga-DOTATATE, which is probably due to the retention in the liver and spleen. Our results revealed some differences between female and male rat data, which, at least in part, may be explained by the small sample size.
Literature
1.
go back to reference Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2012;39:S11–30.CrossRefPubMed Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2012;39:S11–30.CrossRefPubMed
2.
go back to reference Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46 Suppl 1:172S–8.PubMed Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46 Suppl 1:172S–8.PubMed
3.
go back to reference Meyer GJ, Mäcke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004;8:1097–104. Meyer GJ, Mäcke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004;8:1097–104.
4.
go back to reference Roivainen A, Jalkanen S, Nanni C. Gallium-labelled peptides for imaging of inflammation. Eur J Nucl Med Mol Imaging. 2012;39:S68–77.CrossRefPubMed Roivainen A, Jalkanen S, Nanni C. Gallium-labelled peptides for imaging of inflammation. Eur J Nucl Med Mol Imaging. 2012;39:S68–77.CrossRefPubMed
5.
go back to reference Uchino E, Tsuzuki T, Inoue K. The effects of age and sex on seven elements of Sprague-Dawley rat organs. Lab Anim. 1990;24:253–64.CrossRefPubMed Uchino E, Tsuzuki T, Inoue K. The effects of age and sex on seven elements of Sprague-Dawley rat organs. Lab Anim. 1990;24:253–64.CrossRefPubMed
6.
go back to reference Velikyan I, Xu H, Nair M, Hall H. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Nucl Med Biol. 2012;39:628–39. Velikyan I, Xu H, Nair M, Hall H. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Nucl Med Biol. 2012;39:628–39.
7.
go back to reference Ujula T, Salomäki S, Autio A, Luoto P, Tolvanen T, Lehikoinen P, et al. 68Ga-chloride PET reveals human pancreatic adenocarcinoma xenografts in rats—comparison with FDG. Mol Imaging Biol. 2010;12:259–68.CrossRefPubMed Ujula T, Salomäki S, Autio A, Luoto P, Tolvanen T, Lehikoinen P, et al. 68Ga-chloride PET reveals human pancreatic adenocarcinoma xenografts in rats—comparison with FDG. Mol Imaging Biol. 2010;12:259–68.CrossRefPubMed
8.
go back to reference Silvola JM, Laitinen I, Sipilä HJ, Laine VJ, Leppänen P, Ylä-Herttuala S, et al. Uptake of 68gallium in atherosclerotic plaques in LDLR−/−ApoB100/100 mice. EJNMMI Res. 2011;1:14.CrossRefPubMedPubMedCentral Silvola JM, Laitinen I, Sipilä HJ, Laine VJ, Leppänen P, Ylä-Herttuala S, et al. Uptake of 68gallium in atherosclerotic plaques in LDLR−/−ApoB100/100 mice. EJNMMI Res. 2011;1:14.CrossRefPubMedPubMedCentral
9.
go back to reference Nanni C, Errani C, Boriani L, Fantini L, Ambrosini V, Boschi S, et al. 68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. J Nucl Med. 2010;51:1932–6.CrossRefPubMed Nanni C, Errani C, Boriani L, Fantini L, Ambrosini V, Boschi S, et al. 68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. J Nucl Med. 2010;51:1932–6.CrossRefPubMed
10.
go back to reference Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72–9.CrossRefPubMed Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72–9.CrossRefPubMed
11.
go back to reference Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin. 2009;48:201–7.PubMed Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin. 2009;48:201–7.PubMed
12.
go back to reference Sandström M, Velikyan I, Garske-Román U, Sörensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54:1755–9.CrossRefPubMed Sandström M, Velikyan I, Garske-Román U, Sörensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54:1755–9.CrossRefPubMed
13.
go back to reference Xavier C, Vaneycken I, D’huyvetter M, Heemskerk J, Keyaerts M, Vincke C, et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54:776–84.CrossRefPubMed Xavier C, Vaneycken I, D’huyvetter M, Heemskerk J, Keyaerts M, Vincke C, et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54:776–84.CrossRefPubMed
14.
go back to reference Roivainen A, Kähkönen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867–72.CrossRefPubMed Roivainen A, Kähkönen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867–72.CrossRefPubMed
15.
go back to reference International Commission on Radiological Protection. ICRP Publication 80. Recalculated dose data for 19 frequently used radiopharmaceuticals from ICRP publication 53. Ann ICRP. 1998;28:47–83.CrossRef International Commission on Radiological Protection. ICRP Publication 80. Recalculated dose data for 19 frequently used radiopharmaceuticals from ICRP publication 53. Ann ICRP. 1998;28:47–83.CrossRef
16.
go back to reference Mird-dose estimate report no. 2. Summary of current radiation dose estimates to humans from 66Ga-, 68Ga-, and 72Ga-citrate. J Nucl Med. 1973;14:755–6. Mird-dose estimate report no. 2. Summary of current radiation dose estimates to humans from 66Ga-, 68Ga-, and 72Ga-citrate. J Nucl Med. 1973;14:755–6.
17.
go back to reference Parsey RV, Sokol LO, Bélanger MJ, Kumar JS, Simpson NR, Wang T, et al. Amyloid plaque imaging agent [C-11]-6-OH-BTA-1: biodistribution and radiation dosimetry in baboon. Nucl Med Commun. 2005;26:875–80.CrossRefPubMed Parsey RV, Sokol LO, Bélanger MJ, Kumar JS, Simpson NR, Wang T, et al. Amyloid plaque imaging agent [C-11]-6-OH-BTA-1: biodistribution and radiation dosimetry in baboon. Nucl Med Commun. 2005;26:875–80.CrossRefPubMed
18.
go back to reference Scheinin NM, Tolvanen TK, Wilson IA, Arponen EM, Någren KÅ, Rinne JO. Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med. 2007;48:128–33.PubMed Scheinin NM, Tolvanen TK, Wilson IA, Arponen EM, Någren KÅ, Rinne JO. Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med. 2007;48:128–33.PubMed
19.
go back to reference Santens P, De Vos F, Thierens H, Decoo D, Slegers G, Dierckx RA, et al. Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. J Nucl Med. 1998;39:307–10.PubMed Santens P, De Vos F, Thierens H, Decoo D, Slegers G, Dierckx RA, et al. Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. J Nucl Med. 1998;39:307–10.PubMed
20.
go back to reference Harvey J, Firnau G, Garnett ES. Estimation of the radiation dose in man due to 6-18F-Fluoro-L-Dopa. J Nucl Med. 1985;26:931–5.PubMed Harvey J, Firnau G, Garnett ES. Estimation of the radiation dose in man due to 6-18F-Fluoro-L-Dopa. J Nucl Med. 1985;26:931–5.PubMed
21.
go back to reference Brown WD, Oakes TR, DeJesus OT, Taylor MD, Roberts AD, Nickles RJ, et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med. 1998;39:1884–91.PubMed Brown WD, Oakes TR, DeJesus OT, Taylor MD, Roberts AD, Nickles RJ, et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med. 1998;39:1884–91.PubMed
22.
go back to reference Tang G, Wang M, Tang X, Luo L, Gan M. Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-L-tyrosine as oncologic PET tracer. Appl Radiat Isotopes. 2003;58:219–25.CrossRef Tang G, Wang M, Tang X, Luo L, Gan M. Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-L-tyrosine as oncologic PET tracer. Appl Radiat Isotopes. 2003;58:219–25.CrossRef
23.
go back to reference Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Müller HW, et al. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging. 2003;30:519–24.CrossRefPubMed Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Müller HW, et al. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging. 2003;30:519–24.CrossRefPubMed
24.
go back to reference Tolvanen T, Yli-Kerttula T, Ujula T, Autio A, Lehikoinen P, Minn H, et al. Biodistribution and radiation dosimetry of [11C]choline: a comparison between rat and human data. Eur J Nucl Med Mol Imaging.2010;37:874–83.CrossRefPubMed Tolvanen T, Yli-Kerttula T, Ujula T, Autio A, Lehikoinen P, Minn H, et al. Biodistribution and radiation dosimetry of [11C]choline: a comparison between rat and human data. Eur J Nucl Med Mol Imaging.2010;37:874–83.CrossRefPubMed
25.
go back to reference Leggett RW. Reliability of the ICRP’s dose coefficients for members of the public. 1. Sources of uncertainty in the biokinetic models. Radiat Prot Dosimetry. 2001;95:199–213.CrossRefPubMed Leggett RW. Reliability of the ICRP’s dose coefficients for members of the public. 1. Sources of uncertainty in the biokinetic models. Radiat Prot Dosimetry. 2001;95:199–213.CrossRefPubMed
Metadata
Title
Absorption, distribution and excretion of intravenously injected 68Ge/68Ga generator eluate in healthy rats, and estimation of human radiation dosimetry
Authors
Anu Autio
Helena Virtanen
Tuula Tolvanen
Heidi Liljenbäck
Vesa Oikonen
Tiina Saanijoki
Riikka Siitonen
Meeri Käkelä
Andrea Schüssele
Mika Teräs
Anne Roivainen
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2015
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-015-0117-z

Other articles of this Issue 1/2015

EJNMMI Research 1/2015 Go to the issue